Dysregulated release by neutrophils of sticky aggregates of DNA/protein called “NETs” directly contributes to mechanisms of autoimmune, inflammatory, infectious, and malignant disease. Current NET therapies are limited and toxic. We developed Deoxymab, a first-in-class antibody that penetrates neutrophil nuclei, binds DNA, and prevents release of NETs without perturbing other neutrophil functions. Deoxymab master cell bank and GMP manufacturing procedures are established, and a Deoxymab fragment already passed toxicology studies in rodents and primates.